# Ceretype Neuromedicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ceretype-neuromedicine

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.ceretype.com
- Total disclosed funding: $2M
- Latest round: Seed (Jan 4, 2024)
- Investors on record: 3

## About

Founded in 2020 and based in Massachusetts, US, Ceretype Neuromedicine, Inc. operates as a neuropsychiatric drug development company that develops therapeutics for psychiatric patients. The company was founded by its CEO, Emily Stern, and David Silbersweig. In January 2024, Ceretype Neuromedicine, Inc. raised USD 2 million in seed funding led by Cedar Street Group, One Mind Accelerator, and Leafy Tunnel.

Ceretype Neuromedicine offers a functional magnetic resonance imaging (fMRI) platform, which is a brain imaging technology platform that provides biologically based therapeutic insights for patients with psychiatric and neurological disorders. The company also offers brain insight reports, or functional brain maps, which give each patient unique insights that may help develop biomarkers for psychiatric and neurological conditions.

The company plans to use the funds raised in January 2024 to support the improvement of its drug and patient care, as well as to make its solution more accessible.

## Funding rounds

- Seed, Jan 4, 2024, $2M — Cedar Street Group, Leafy Tunnel, One Mind

## Investors

- Cedar Street Group (https://capitalatlas.ai/funds/cedar-street-group) — Seed
- Leafy Tunnel (https://capitalatlas.ai/funds/leafy-tunnel) — Seed
- One Mind (https://capitalatlas.ai/funds/one-mind) — Seed